

The practical approach to neurogenic LUTD

Poster Session 52

Sunday, 13 March
15:45 - 17:15

Location: Room 14a (ICM, Level 1)

Chairs: T.M. Kessler, Zürich (CH)
A.M.M.S. Tayib, Jeddah (SA)
G. Van Koeveringe, Maastricht (NL)

Aims and objectives of this presentation

Overview of new approaches and longterm outcome in neurogenic patients.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 646 **Effect of early sacral and pudendal neuromodulation on lower urinary tract and spinal cord in spinal cord injury mini pigs**
By: [Foditsch E.E.](#)¹, [Patras I.](#)², [Hutu I.](#)², [Bauer S.](#)¹, [Roider K.](#)¹, [Sievert K-D.](#)¹, [Zimmermann R.](#)¹
Institutes:¹Paracelsus Medical University, Dept. of Urology and Andrology, Salzburg, Austria, ²Banat University of Agronomical Sciences and Veterinary Medicine, Dept. of Animal Productions and Veterinary Public Health, Timisoara, Romania
- 647 **Efficacy and safety of onabotulinumtoxinA 100U for treatment of urinary incontinence due to neurogenic detrusor overactivity in non-catheterising multiple sclerosis patients**
By: [Chartier-Kastler E.](#)¹, [Denys P.](#)², [Keppenne V.](#)³, [Brucker B.](#)⁴, [Egerdie B.](#)⁵, [Magyar A.](#)⁶, [Nicando J.P.](#)⁷, [Jenkins B.](#)⁷, [Kohan A.](#)⁸
Institutes:¹Université Paris-VI, Dept. of Urology, Paris, France, ²Hôpital Raymond Poincaré, Dept. of Neuro-Urology, Garches, France, ³Université De Liège, Dept. of Urology, Liège, Belgium, ⁴New York University, Dept. of Urology and Obstetrics and Gynaecology, New York, United States of America, ⁵Urology Associates/Urologic Med Research, Dept. of Urology, Ontario, Canada, ⁶Allergan Plc, Dept. of Biostatistics, Bridgewater, United States of America, ⁷Allergan Plc, Dept. of Urology, Irvine, United States of America, ⁸Advanced Urology Centers of New York, Dept. of Urology, Bethpage, United States of America
- 648 **Lower urinary tract dysfunction is the major concern of adult patients with spina bifida: Data from a prospective cohort of 371 patients**
By: [Peyronnet B.](#)¹, [Brochard C.](#)², [Jezequel M.](#)³, [Ménard H.](#)³, [Dampousse M.](#)⁴, [Bonan I.](#)⁴, [Kerdran J.](#)⁴, [Siproudhis L.](#)², [Gamé X.](#)⁵, [Manunta A.](#)¹
Institutes:¹CHU Rennes, Dept. of Urology, Rennes, France, ²CHU Rennes, Dept. of Gastrology, Rennes, France, ³CHU Rennes, Referral Center For Spina Bifida, Rennes, France, ⁴CHU Rennes, Dept. of Physical Medicine, Rennes, France, ⁵CHU Toulouse, Dept. of Urology, Toulouse, France
- 649 **Bacteriuria in patients undergoing intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity: Do we need antibiotic prophylaxis?**
By: [Leitner L.](#)¹, [Sammer U.](#)², [Walter M.](#)², [Knüpfer S.](#)², [Schneider M.P.](#)³, [Seifert B.](#)⁴, [Mehnert U.](#)², [Kessler T.M.](#)²
Institutes:¹Balgrist University Hospital and University Hospital of Basel, Dept. of Neuro-Urology and Urology, Zürich and Basel, Switzerland, ²Balgrist University Hospital, Dept. of Neuro-Urology, Zürich, Switzerland, ³ETH Zürich, Brain Research Institute, Zürich, Switzerland, ⁴University of Zürich, Dept. of Biostatistics and Prevention, Zürich, Switzerland
- 651 **Urodynamic findings in amiotrophic lateral sclerosis patients with lower urinary tract symptoms**
By: [Arlandis S.](#)¹, [Vazquez-Costa J.F.](#)², [Martinez-Cuenca E.](#)¹, [Sevilla T.](#)², [Boronat F.](#)¹, [Broseta E.](#)¹
Institutes:¹Hospital Universitari i Politècnic La Fe, Dept. of Urology, Valencia, Spain, ²Hospital

Universitari i Politècnic La Fe, Dept. of Neurology, Valencia, Spain

- 652 **Intradetrusor injections of onabotulinum toxin A (Botox®) 300 u or 200 u versus abobotulinum toxin A (Dysport®) 750 u in the management of neurogenic detrusor overactivity: A case control study**
 By: Peyronnet B.¹, Castel-Lacanal E.², Roumiquié M.³, Even L.³, Guillotreau J.³, Marque P.², Soulié M.⁴, Rischmann P.⁴, Gamé X.⁴
 Institutes:¹CHU Rennes, Dept. of Urology, Rennes, France, ²CHU Toulouse, Dept. of Physical Medicine, Toulouse, France, ³CHU Toulouse, Dept. of Urology, Toulouse, France, ⁴CHU Toulouse, Dept. of Urology, Toulouse, France
- 653 **Urinary and sexual dysfunction in patients affected by Parkinson's disease**
 By: Gubbiotti M.¹, Rossi De Vermandois J.A.¹, Boni A.¹, Proietti S.², Conte A.³, Berardelli A.³, Giannantoni A.¹
 Institutes:¹University of Perugia, Dept. of Surgical and Biomedical Sciences, Perugia, Italy, ²Pierre and Marie Curie University, Tenon Hospital, Dept. of Urology, Paris, France, ³Sapienza University of Rome, Dept. of Neurology and Psychiatry, Rome, Italy
- 654 **Is an early anticholinergic treatment able to prevent detrusor overactivity after spinal cord transection in rats?**
 By: Biardeau X., Aharony S., Loutochin O., Campeau L., Corcos J.
 Institutes: Jewish General Hospital, Dept. of Urology, Montreal, Canada
- 655 **Impairment of sensory nerves by onabotulinumtoxinA improves neurogenic detrusor overactivity following spinal cord injury**
 By: Coelho A.¹, Oliveira R.², Cruz E.¹, Cruz C.²
 Institutes:¹University of Porto, Dept. of Renal, Urologic and Infectious Diseases, Porto, Portugal, ²University of Porto, Dept. of Experimental Biology, Porto, Portugal
- 656 **Mirabegron and refractory neurogenic urinary incontinence**
 By: Andretta E.¹, Virdone S.², Filocamo M.T.³, Zuliani C.⁴, Artuso G.¹
 Institutes:¹General Hospital Ulss 13 Veneto, Dept. of Urology, Dolo, Italy, ²CRO National Cancer Institute, Dept. of Epidemiology, Aviano, Italy, ³General Hospital, Dept. of Urology, Savigliano, Italy, ⁴General Hospital Ulss 13 Veneto, Dept. of Neurology, Mirano, Italy
- 657 **More than 15 years experience with intradetrusor onabotulinumtoxinA injections for treating refractory neurogenic detrusor overactivity: Lessons to be learned**
 By: Tornic J.¹, Leitner L.², Guggenbühl S.¹, Walter M.¹, Knüpfer S.¹, Schneider M.P.³, Mehnert U.¹, Kessler T.M.¹
 Institutes:¹Balgrist University Hospital, Dept. of Neuro-Urology, Zürich, Switzerland, ²Balgrist University Hospital and University Hospital of Basel, Dept. of Neuro-Urology/Urology, Zürich and Basel, Switzerland, ³ETH Zürich, Brain Research Institute, Zürich, Switzerland
- 658 **Risks factors for recurrent urinary tract infections in patients with multiple sclerosis**
 By: Phé V.¹, Curtis C.², Neha S.¹, Porter B.³, Chataway J.³, Panicker J.¹, Pakzad M.¹
 Institutes:¹The National Hospital For Neurology and Neurosurgery, Dept. of Uro-Neurology and UCL Institute of Neurology, London, United Kingdom, ²University College London Hospital, Dept. of Microbiology, London, United Kingdom, ³The National Hospital For Neurology and Neurosurgery, Dept. of Neurology and UCL Institute of Neurology, London, United Kingdom
- 659 **Pudendal nerve neuromodulation: Where do we stand? Trends after analysis of a ten year experience**
 By: Renard J.E.E.¹, Citeri M.², Zanollo L.², Guerrer C.², Rizzato L.², Frediani L.², Iselin C.¹, Spinelli M.²
 Institutes:¹Hôpitaux Universitaires de Genève, Dept. of Urology, Genève, Switzerland, ²Niguarda Hospital, Spinal Unit, A. Zanollo Center for Sacral Area Dysfunctions, Milan, Italy
- 17:04 - 17:11 **Summary and context**
 T.M. Kessler, Zürich (CH)